- Home
- RLAY vs GAIN Comparison
RLAY vs GAIN Comparison
Compare RLAY & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- GAIN
- Stock Information
- Founded
- RLAY 2015
- GAIN 2005
- Country
- RLAY United States
- GAIN United States
- Employees
- RLAY N/A
- GAIN N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- GAIN Finance: Consumer Services
- Sector
- RLAY Health Care
- GAIN Finance
- Exchange
- RLAY Nasdaq
- GAIN Nasdaq
- Market Cap
- RLAY 619.0M
- GAIN 522.8M
- IPO Year
- RLAY 2020
- GAIN 2005
- Fundamental
- Price
- RLAY $4.12
- GAIN $14.21
- Analyst Decision
- RLAY Strong Buy
- GAIN Buy
- Analyst Count
- RLAY 13
- GAIN 2
- Target Price
- RLAY $18.00
- GAIN $14.00
- AVG Volume (30 Days)
- RLAY 1.5M
- GAIN 139.1K
- Earning Date
- RLAY 11-05-2025
- GAIN 11-06-2025
- Dividend Yield
- RLAY N/A
- GAIN 15.48%
- EPS Growth
- RLAY N/A
- GAIN 8.96
- EPS
- RLAY N/A
- GAIN 2.16
- Revenue
- RLAY $8,355,000.00
- GAIN $95,028,000.00
- Revenue This Year
- RLAY $31.55
- GAIN $6.70
- Revenue Next Year
- RLAY N/A
- GAIN $5.50
- P/E Ratio
- RLAY N/A
- GAIN $6.57
- Revenue Growth
- RLAY N/A
- GAIN 6.55
- 52 Week Low
- RLAY $1.78
- GAIN $11.42
- 52 Week High
- RLAY $10.72
- GAIN $15.34
- Technical
- Relative Strength Index (RSI)
- RLAY 65.83
- GAIN 54.28
- Support Level
- RLAY $3.52
- GAIN $13.92
- Resistance Level
- RLAY $4.26
- GAIN $14.20
- Average True Range (ATR)
- RLAY 0.22
- GAIN 0.16
- MACD
- RLAY 0.07
- GAIN 0.00
- Stochastic Oscillator
- RLAY 85.26
- GAIN 60.42
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.